QuanMedAI
Menu

MenaQ7 Vitamin K2 MK-7: What Cardiovascular Trials Actually Show

MenaQ7 is the most clinically studied vitamin K2 form. Here is a full review of the arterial stiffness, calcification, and MGP activation evidence from randomised trials.

By Dr. Elena Marsh, Health Technology Correspondent

Published: November 18, 2026 · 10 min read

Quick Answer

MenaQ7 at 180 μg/day for 3 years significantly reduced arterial stiffness (pulse wave velocity) in postmenopausal women in the landmark Knapen 2015 RCT — the strongest cardiovascular trial evidence for any vitamin K2 supplement. MenaQ7 activates matrix Gla protein (MGP), the vascular calcification inhibitor that requires vitamin K2 for carboxylation. It does not reverse established coronary calcification (VitaK-CAC 2019). Patients on warfarin should not use K2 supplements without medical supervision.

Why Is Vitamin K2 Important for Cardiovascular Health?

Vascular calcification — the deposition of calcium-phosphate crystals in arterial walls — is a major driver of cardiovascular mortality that is distinct from atherosclerotic plaque development. Arterial calcification increases vessel stiffness, elevates pulse wave velocity, raises systolic blood pressure, and independently predicts myocardial infarction and all-cause mortality after adjustment for traditional risk factors. For decades, calcification was considered irreversible and simply a marker of advanced disease. The discovery of matrix Gla protein (MGP) — a potent inhibitor of arterial calcification that requires vitamin K2 for activation — changed this view: it opened the possibility that vitamin K2 supplementation could modulate calcification risk in living tissue.

The Rotterdam Study (2004) provided the first major epidemiological evidence: in 4,807 elderly Dutch residents followed for over a decade, those in the highest tertile of dietary vitamin K2 (menaquinone) intake had 41% lower coronary heart disease mortality, 57% lower aortic calcification, and 26% lower all-cause mortality than those in the lowest tertile. Vitamin K1 intake showed no comparable association. This dietary signal drove a generation of vitamin K2 supplementation trials, with MenaQ7 (menaquinone-7, 180 μg/day) emerging as the most studied compound.

What Did the Key MenaQ7 Randomised Trials Find?

Three randomised controlled trials with MenaQ7 form the core of the cardiovascular evidence base:

Knapen et al. 2015 (Thrombosis and Haemostasis) — the landmark trial: 244 healthy postmenopausal women, 3 years, 180 μg MenaQ7 vs placebo. Primary endpoint: pulse wave velocity (carotid-femoral, a validated arterial stiffness measure). Result: PWV decreased by 0.37 m/s in MenaQ7 vs a 0.06 m/s increase in placebo (p<0.001). Carboxylated MGP increased 68% vs 11%. Conclusion: MenaQ7 supplementation significantly reduced arterial stiffness progression and activated vascular calcification inhibition machinery over 3 years.

VitaK-CAC trial 2019 (JACC: Cardiovascular Imaging): 497 patients with established CAC scores 11–400, 2 years, 180 μg MK-7 vs placebo. Primary endpoint: CAC score progression. Result: No statistically significant difference in CAC progression between groups. Conclusion: MK-7 at this dose does not reverse established coronary calcification — consistent with the hypothesis that vitamin K2 prevents new calcification but cannot dissolve existing deposits.

Westenfeld et al. 2012 (CJASN): Haemodialysis patients — a population with very high arterial calcification burden — given 360 μg MK-7 daily. Inactive MGP (the uncalboxylated form associated with calcification risk) decreased by 46% over 6 weeks, confirming dose-dependent MGP carboxylation in a high-risk population. No hard cardiovascular endpoint data from this study.

TrialnDurationPrimary outcomeResult
Knapen 20152443 yearsArterial stiffness (PWV)Significant ↓ (p<0.001)
VitaK-CAC 20194972 yearsCAC score progressionNo significant difference
Westenfeld 2012536 weeksInactive MGP (dp-ucMGP)−46% (p<0.001)

What Is Matrix Gla Protein and Why Does It Matter?

Matrix Gla protein (MGP) is a small extracellular matrix protein expressed in vascular smooth muscle cells and chondrocytes. It is the most potent known inhibitor of vascular calcification: MGP knockout mice develop calcified arteries so severe they die of cardiovascular failure within 2 months of birth, while mice overexpressing MGP are fully protected from induced arterial calcification. MGP must be carboxylated (activated) by vitamin K2 to function. In vitamin K2-insufficient states, uncarboxylated MGP (ucMGP) accumulates in vessel walls and fails to block calcium crystal deposition.

Circulating dp-ucMGP (dephosphorylated, uncarboxylated MGP) is now used as a biomarker of vitamin K2 tissue insufficiency. Population data show that the majority of adults in Western countries have dp-ucMGP levels in the range associated with elevated cardiovascular risk — a finding interpreted as widespread functional vitamin K2 insufficiency. This is the mechanistic rationale for MenaQ7 supplementation trials: by correcting tissue MK-7 levels, the trials aim to shift the MGP carboxylation status and thereby reduce vascular calcification risk.

Key Sources

  • Knapen MHJ et al. — MenaQ7 and arterial stiffness — Thrombosis and Haemostasis (2015)
  • van Ballegooijen AJ et al. — VitaK-CAC trial — JACC: Cardiovascular Imaging (2019)
  • Westenfeld R et al. — MK-7 in haemodialysis — CJASN (2012)
  • Geleijnse JM et al. — Rotterdam Study dietary menaquinone — Journal of Nutrition (2004)
  • Keyzer CA et al. — EPIC-NL cohort vitamin K2 — European Heart Journal (2021)

Frequently Asked Questions

Deep Dive

Longevity Supplements: Evidence Review

Our comprehensive guide covers the science, protocols, and tools in detail — with FAQs answered by our research team.

Read the Full Guide →

© 2026 QuanMed - All rights reserved